CAS Number648450-29-7
SynonymsAS605240; (5Z)-5-(Quinoxalin-6-ylmethylene)-1,3-thiazolidine-2,4-dione; (5Z)-5-(6-Quinoxalinylmethylene)-1,3-thiazolidine-2,4-dione; 5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione; AS 605240; AS-605240
Molecular FormulaC12H7N3O2S
Molecular Weight257.268
Density1.6±0.1 g/cm3
Appearance, faint red to orange to dark brown
Symbol
Signal WordWarning
| Chemical & Physical Properties | |
|---|---|
| CAS Number | 648450-29-7 |
| Catalog No. | 2A-1170288 |
| Chinese Name | 5-(6-喹喔啉亚甲基)-2,4-噻唑啉二酮 |
| Synonyms | AS605240; (5Z)-5-(Quinoxalin-6-ylmethylene)-1,3-thiazolidine-2,4-dione; (5Z)-5-(6-Quinoxalinylmethylene)-1,3-thiazolidine-2,4-dione; 5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione; AS 605240; AS-605240 |
| Molecular Formula | C12H7N3O2S |
| Molecular Weight | 257.268 |
| Density | 1.6±0.1 g/cm3 |
| Appearance | , faint red to orange to dark brown |
| Water Solubility | DMSO: soluble1mg/mL, clear (warmed) |
| Storage Condition | 2-8°C |
| Application | AS-605240 is an orally available and specific PI3Kγ inhibitor with an IC50 value of 8 nM and a Ki value of 7.8 nM. |
| PubChem ID | 15392284 |
| SMILES | O=C1NC(=O)C(=Cc2ccc3nccnc3c2)S1 |
| InChI | InChI=1S/C12H7N3O2S/c16-11-10(18-12(17)15-11)6-7-1-2-8-9(5-7)14-4-3-13-8/h1-6H,(H,15,16,17)/b10-6+ |
| InChI Key | SQWZFLMPDUSYGV-UXBLZVDNSA-N |
| Hazard Symbols | transportation |
| MSDS | msds/170438_2_648450_29_7.pdf |
| Bioactivity | AS-605240 is a specific and orally active inhibitor of the PI3Kγ, with an IC50 of 8 nM, and a Ki of 7.8 nM. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Research Areas >> Cancer Target PI3Kγ:8 nM (IC50) PI3Kα:60 nM (IC50) PI3Kβ:270 nM (IC50) PI3Kδ:300 nM (IC50) Autophagy In Vitro AS-605240 is an isoform-selective inhibitor of PI3Kγ with over 30-fold selectivity for PI3Kδ and β, and 18- and 7.5-fold selectivity over PI3Kα, respectively. AS-605240 shows an inhibitory effect on C5a-mediated PKB phosphorylation in RAW264 mouse macrophages with an IC50 of 0.09 μM. AS-605240 blocks PKB phosphorylation induced by MCP-1 and has little or no effect after stimulation with CSF-1. AS-605240 inhibits MCP-1-mediated phosphorylation of PKB and its downstream substrates GSK3α and β in a concentration-dependent manner. AS605240 suppresses in a dose-dependent manner the proliferation of BDC2.5 CD4+ T cells[2]. In Vivo AS-605240 (30 mg/kg BW, per os, every 12 h) markedly decreases FoxM1 expression in mouse lungs and fails to restore vascular integrity[1]. AS-605240 reduces RANTES-induced peritoneal neutrophil recruitment, with ED50 of 9.1 mg/kg. In the CCL5 model, AS-605240 shows an ED50 value of 10 mg/kg, in correlation with the percentage of reduction of neutrophil recruitment observed in Pik3cg-/- mice. AS-605240 (50 mg/kg, p.o.) substantially reduces clinical and histological signs of joint inflammation to a similar extent to that of Pik3cg-/- mice[2]. AS605240 (30 mg/kg, i.p.) suppresses intracellular PAkt in splenocytes of NOD mice and delays diabetes onset. AS605240 also prevents autoimmune diabetes in prediabetic NOD mice, and suppresses autoreactive T cells while increasing Tregs in NOD mice. AS605240 (30 mg/kg, i.p.) reverses hyperglycemia in newly hyperglycemic NOD mice, reverses hyperglycemia in early diabetic NOD mice through Tregs and suppresses T-cell infiltration in pancreatic islets while increasing Tregs[3]. AS605240 (25, 50 mg/kg) markedly reduces total cell count and numbers of macrophages, neutrophils and lymphocytes in rats. AS605240 significantly reduces the levels of TNF-α and IL-1β in BALF to 132.7±11.2 pg/mL and 49.2±11.3 pg/mL in 25 mg/kg AS605240 + BLM group and 131.3±10.7 and 49.6±8.8 pg/mL in 50 mg/kg AS605240 + BLM group, respectively. AS605240 inhibits prefibrotic cytokines production in bleomycin-induced pulmonary fibrosis. AS605240 inhibits phosphorylation of Akt of inflammatory cells in bleomycin-induced pulmonary fibrosis model[4]. Kinase Assay Human PI3Kγ (100 ng) is incubated at RT with kinase buffer (10 mM MgCl2, 1 mM β-glycerophosphate, 1 mM DTT, 0.1 mM Na3VO4, 0.1% Na Cholate and 15 M ATP/100 nCi γ[33P]ATP, final concentrations) and lipid vesicles containing 18 M PtdIns and 250 M of PtdSer (final concentrations), in the presence of inhibitors or DMSO. Kinase reaction is stopped by adding 250 g of Neomycin-coated Scintillation Proximity Assay (SPA) bead and proceeded. Cell Assay A total of 5×105 BDC2.5 splenocytes and 50 μg/mL BDC2.5-peptide are incubated in vitro in a 96-well round-bottom plate for 48 h. Then the cultures are pulsed with 1 μCi of tritiated thymidine [3H] to determine cell proliferation. Animal Admin In this study, rats are bred for one week to affirm body weight and then randomLy divided into four experimental groups: (a) control group (rats are given vehicle only); (b) BLM group (rats are induced with BLM); (c) BLM + 25 mg/kg AS605240 group (rats are induced with BLM and then administrated with 25 mg/kg AS605240); (d) BLM + 50 mg/kg AS605240 group (the same protocol as the former group except a different dose of 50 mg/kg AS605240). In addition, five rats are given 50 mg/kg AS605240 only to detect whether AS605240 has any side effect simultaneously as the previous four groups. Rats in (c), (d) and AS605240-given-only group are administered orally 25, 50 and 50 mg/kg AS605240 by gavage while rats in control group and BLM group are given only equivalent saline at day-1 (the day rats are given BLM is marked as day-0). The same dosage is maintained once everyday for 28 days. References [1]. Huang X, et al. Endothelial p110γPI3K Mediates Endothelial Regeneration and Vascular Repair After Inflammatory Vascular Injury. Circulation. 2016 Mar 15;133(11):1093-103. [2]. Camps M, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med. 2005 Sep;11(9):936-43. [3]. Azzi J, et al. The novel therapeutic effect of phosphoinositide 3-kinase-γ inhibitor AS605240 in autoimmune diabetes. Diabetes. 2012 Jun;61(6):1509-18. Epub 2012 Mar 8. [4]. Wei X, et al. A phosphoinositide 3-kinase-gamma inhibitor, AS605240 prevents bleomycin-induced pulmonary fibrosis in rats. Biochem Biophys Res Commun. 2010 Jun 25;397(2):311-7. Epub 2010 May 26. Chemical & Physical Properties Density 1.6±0.1 g/cm3 Molecular Formula C12H7N3O2S Molecular Weight 257.268 Exact Mass 257.025909 PSA 97.25000 LogP 0.52 Appearance of Characters , faint red to orange to dark brown Index of Refraction 1.792 InChIKey SQWZFLMPDUSYGV-UXBLZVDNSA-N SMILES O=C1NC(=O)C(=Cc2ccc3nccnc3c2)S1 Storage condition 2-8°C Water Solubility DMSO: soluble1mg/mL, clear (warmed) |
| Use of | AS-605240 is a specific and orally active inhibitor of the PI3Kγ, with an IC50 of 8 nM, and a Ki of 7.8 nM. Properties Name 5-(6-Quinoxalinylmethylene)-2,4-thiazolidine-2,4-dione Synonym More Synonyms AS-605240 Biological Activity Description AS-605240 is a specific and orally active inhibitor of the PI3Kγ, with an IC50 of 8 nM, and a Ki of 7.8 nM. Related Catalog Signaling Pathways >> Autophagy >> Autophagy Research Areas >> Cancer PI3Kγ:8 nM (IC50) PI3Kα:60 nM (IC50) PI3Kβ:270 nM (IC50) PI3Kδ:300 nM (IC50) Cell Assay A total of 5×105 BDC2.5 splenocytes and 50 μg/mL BDC2.5-peptide are incubated in vitro in a 96-well round-bottom plate for 48 h. Then the cultures are pulsed with 1 μCi of tritiated thymidine [3H] to determine cell proliferation. References [1]. Huang X, et al. Endothelial p110γPI3K Mediates Endothelial Regeneration and Vascular Repair After Inflammatory Vascular Injury. Circulation. 2016 Mar 15;133(11):1093-103. [2]. Camps M, et al. Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med. 2005 Sep;11(9):936-43. [3]. Azzi J, et al. The novel therapeutic effect of phosphoinositide 3-kinase-γ inhibitor AS605240 in autoimmune diabetes. Diabetes. 2012 Jun;61(6):1509-18. Epub 2012 Mar 8. [4]. Wei X, et al. A phosphoinositide 3-kinase-gamma inhibitor, AS605240 prevents bleomycin-induced pulmonary fibrosis in rats. Biochem Biophys Res Commun. 2010 Jun 25;397(2):311-7. Epub 2010 May 26. Chemical & Physical Properties Molecular Formula C12H7N3O2S Exact Mass 257.025909 PSA 97.25000 Appearance of Characters , faint red to orange to dark brown Index of Refraction 1.792 InChIKey SQWZFLMPDUSYGV-UXBLZVDNSA-N |
| Transport Info | Product name: Purity: 98.0% |
| MSDS Transport Info | Module 14. Shipping information 14.1 UN dangerous goods number European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.2 Names specified by the United Nations (UN) European Land Transport Dangerous Regulations: Non-dangerous goods IMDG Code: Non-dangerous goods International air transport dangerous goods regulations: non-dangerous goods 14.3 Transport hazard categories European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.4 Package group European Land Transport Dangerous Regulations: -International Maritime Dangerous Regulations: -International Air Transport Dangerous Regulations: - 14.5 Environmental hazards European Land Transport Dangerous Regulations: No International Maritime Transport Dangerous Regulations Maritime Pollutants: No International Air Transport Risk Regulations: No 14.6 Special reminder to users No data available |
| Related Products in Specialty Chemicals | ||
|---|---|---|
| GSK1904529A | 1089283-49-7 | 2A-1170283 |
| 2,5-DICHLOROPHENETHYLAMINE | 56133-86-9 | 2A-1170284 |
| VX-702 | 479543-46-9 | 2A-1170284 |
| PF-01367338 | 459868-92-9 | 2A-1170285 |
| A-674563 | 552325-73-2 | 2A-1170287 |
| DIBENZAZEPINE | 209984-56-5 | 2A-1170289 |
| PF-05212384 | 1197160-78-3 | 2A-1170290 |
| LY2886721 | 1262036-50-9 | 2A-1170291 |
| PF-04691502 | 1013101-36-4 | 2A-1170293 |
| PP242 | 1092351-67-1 | 2A-1170294 |
| Browse all Specialty Chemicals products » | ||
Phone:
630-322-8886
630-322-8887
Email:
Office Locations:
Chicago, IL, USA
San Francisco, CA, USA
EN
SDS